Ignite Creation Date:
2025-12-24 @ 7:58 PM
Ignite Modification Date:
2026-01-01 @ 2:05 PM
Study NCT ID:
NCT06962904
Status:
RECRUITING
Last Update Posted:
2025-08-11
First Post:
2025-04-21
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
CDC-9 Inactivated Rotavirus Vaccine (IRV) Microneedle Patch (MNP) in Healthy Adults
Sponsor:
Centers for Disease Control and Prevention
Organization:
Study Overview
Official Title:
A Phase 1 Study to Evaluate the Safety and Immunogenicity of CDC-9 Inactivated Rotavirus Vaccine for Intradermal Administration by Microneedle Patch in Healthy Adults
Status:
RECRUITING
Status Verified Date:
2025-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a study of CDC-9 inactivated rotavirus vaccine (IRV) microneedle patch (MNP) for intradermal administration in healthy adults aged 18 to 45 years at two dose levels in a 3-dose series. The purpose is to determine if it is safe and if the recipient's immune system responds to the vaccine.
Detailed Description:
Rotavirus remains an important cause of gastroenteritis and accounted for 19% of diarrhea-related deaths worldwide in 2019, the majority of which were in low and lower-middle income countries. Although live-attenuated vaccines for rotavirus are available for infants, the immunogenicity and vaccine effectiveness in low- and middle-income countries, where morbidity is highest, is suboptimal. Developing rotavirus vaccination strategies with improved immunogenicity could be advantageous in resource-limited settings.
To improve the safety and efficacy of oral rotavirus vaccines, CDC scientists have developed a human rotavirus strain CDC-9 (G1P\[8\]\^9) that grows to high titer in Vero cells and shows structural stability during manufacturing process. The strain is a single gene natural reassortant with the VP3 gene derived naturally from a G2P\[4\] virus and the other 10 genes from a G1P\[8\] virus, the most common genotype throughout the world. Purified CDC-9 particles when inactivated by heat and administered to the skin using a MNP induced strong serum antibody response, and showed dose sparing effect in mice and rats. This inactivated rotavirus vaccine (IRV) also induced intestinal immunity in mice and prevented fecal shedding in gnotobiotic pigs, thus established the proof of concept for skin vaccination using a MNP against rotavirus. When given in combination with inactivated polio vaccine in mice it did not impair immune responses to either rotavirus or poliovirus serotypes 1, 2, and 3. IRV MNP has been shown to be safe and immunogenic in animal studies.
A rotavirus vaccine with greater efficacy and stronger immunogenic response could further reduce infant mortality and morbidity, and a parenterally administered rotavirus vaccine could minimize interactions from co-administration with polio vaccination. Given the lower immunogenicity and vaccine efficacy of the oral rotavirus vaccines currently licensed by the US and in developing countries and approved for use by the WHO, the IRV presents an opportunity to further prevent rotavirus-associated gastroenteritis in infants.
This will be a Phase 1, randomized, observer blinded, dose escalating, placebo-controlled clinical trial in which healthy adults (18 to 45 years of age) will receive inactivated rotavirus vaccine (IRV) or placebo administered through intradermal inoculation by MNP to determine the safety, reactogenicity, and immunogenicity. Two cohorts, each consisting of 25 individuals (20 vaccine recipients and 5 placebo recipients) will receive 3 intradermal doses by MNP four weeks apart. One cohort will receive 3.75 μg and the other 7.5 μg.
Subjects will receive a total of 3 doses by IRV MNPs or placebo MNPs. These will be administered at Days 1, 29, and 57. Subjects will be monitored for approximately 6 months after the third-dose vaccination. They will be followed for solicited (local and systemic) adverse events (AEs) through 7 days after each dose of vaccine. Unsolicited AEs will be collected through Day 85. Immunogenicity labs will be obtained before each study product dose, 7 days after each dose, 28 days after each dose, 35 days after the first dose, and at the end of study visit (durability of response). Serious adverse events (SAEs), new-onset chronic medical conditions (NOCMCs), and medically attended adverse events (MAAEs) will be followed from study product administration on Day 1 through end of study visit on Day 237. There is no expected overlap with standard-of-care clinical appointments or procedures.
To improve the safety and efficacy of oral rotavirus vaccines, CDC scientists have developed a human rotavirus strain CDC-9 (G1P\[8\]\^9) that grows to high titer in Vero cells and shows structural stability during manufacturing process. The strain is a single gene natural reassortant with the VP3 gene derived naturally from a G2P\[4\] virus and the other 10 genes from a G1P\[8\] virus, the most common genotype throughout the world. Purified CDC-9 particles when inactivated by heat and administered to the skin using a MNP induced strong serum antibody response, and showed dose sparing effect in mice and rats. This inactivated rotavirus vaccine (IRV) also induced intestinal immunity in mice and prevented fecal shedding in gnotobiotic pigs, thus established the proof of concept for skin vaccination using a MNP against rotavirus. When given in combination with inactivated polio vaccine in mice it did not impair immune responses to either rotavirus or poliovirus serotypes 1, 2, and 3. IRV MNP has been shown to be safe and immunogenic in animal studies.
A rotavirus vaccine with greater efficacy and stronger immunogenic response could further reduce infant mortality and morbidity, and a parenterally administered rotavirus vaccine could minimize interactions from co-administration with polio vaccination. Given the lower immunogenicity and vaccine efficacy of the oral rotavirus vaccines currently licensed by the US and in developing countries and approved for use by the WHO, the IRV presents an opportunity to further prevent rotavirus-associated gastroenteritis in infants.
This will be a Phase 1, randomized, observer blinded, dose escalating, placebo-controlled clinical trial in which healthy adults (18 to 45 years of age) will receive inactivated rotavirus vaccine (IRV) or placebo administered through intradermal inoculation by MNP to determine the safety, reactogenicity, and immunogenicity. Two cohorts, each consisting of 25 individuals (20 vaccine recipients and 5 placebo recipients) will receive 3 intradermal doses by MNP four weeks apart. One cohort will receive 3.75 μg and the other 7.5 μg.
Subjects will receive a total of 3 doses by IRV MNPs or placebo MNPs. These will be administered at Days 1, 29, and 57. Subjects will be monitored for approximately 6 months after the third-dose vaccination. They will be followed for solicited (local and systemic) adverse events (AEs) through 7 days after each dose of vaccine. Unsolicited AEs will be collected through Day 85. Immunogenicity labs will be obtained before each study product dose, 7 days after each dose, 28 days after each dose, 35 days after the first dose, and at the end of study visit (durability of response). Serious adverse events (SAEs), new-onset chronic medical conditions (NOCMCs), and medically attended adverse events (MAAEs) will be followed from study product administration on Day 1 through end of study visit on Day 237. There is no expected overlap with standard-of-care clinical appointments or procedures.
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: